ReviewFrontiers in medicine2021
The Variation of SARS-CoV-2 and Advanced Research on Current Vaccines.
Review in Frontiers in medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed.
- Neutralizing antibody response to Omicron subvariants BA.1 and BA.5 in children and adolescents following the two-dose CoronaVac protocol (Immunita-002, Brazil): a 12-month longitudinal study.Frontiers in immunology · 2025Article
- Dynamics of SARS-CoV-2 variants in West Africa: Insights into genomic surveillance in resource-constrained settings.Infection, genetics and evolution : journal of molecular epidemiology and evolutionary genetics in infectious diseases · 2024Review
- A Strategic Framework of SARS-CoV-2 Genomic Surveillance in Bangladesh.Influenza and other respiratory viruses · 2024Article
- Review
- Clinical characteristics and risk factors in patients with SARS-CoV-2 Omicron variant infection complicated with cardiovascular diseases.Frontiers in medicine · 2024Article
- Prenol, but Not Vitamin C, of Fruit Binds to SARS-CoV-2 Spike S1 to Inhibit Viral Entry: Implications for COVID-19.Journal of immunology (Baltimore, Md. : 1950) · 2023Article
- A Comparison of Etiology, Pathogenesis, Vaccinal and Antiviral Drug Development between Influenza and COVID-19.International journal of molecular sciences · 2023Review
- Induction of potent antitumor immunity by intradermal DNA injection using a novel needle-free pyro-drive jet injector.Cancer science · 2023Article
- Anti-Arbovirus Antibodies Cross-React With Severe Acute Respiratory Syndrome Coronavirus 2.Microbiology spectrum · 2022Article
- Uncovering the Impact of Control Strategies on the Transmission Pattern of SARS-CoV-2 - Ruili City, Yunnan Province, China, February-March 2022.China CDC weekly · 2022Article
- Article
- Successful fractionated undiluted doses of COVID-19 vaccine in five cases of suspected allergic reactions to the first dose.Clinical case reports · 2022Article
- Review
- Review
- Factors associated with mortality, length of hospital stay and diagnosis of COVID-19: Data from a field hospital.Journal of infection and public health · 2022Article
- Correlation Analysis of Anti-SARS-CoV-2 RBD IgG and Neutralizing Antibody against SARS-CoV-2 Omicron Variants after Vaccination.Diagnostics (Basel, Switzerland) · 2022Article
- The Importance of Vaccination in the Context of the COVID-19 Pandemic: A Brief Update Regarding the Use of Vaccines.Vaccines · 2022Review
- Determining SARS-CoV-2 non-infectivity state-A brief overview.Frontiers in public health · 2022Review
- Emerging toolset of three-dimensional pulmonary cell culture models for simulating lung pathophysiology towards mechanistic elucidation and therapeutic treatment of SARS-COV-2 infection.Frontiers in pharmacology · 2022Review
- The Emergence of Omicron SARS-CoV-2 Variant (B.1.1.529): The Latest Episode in the COVID-19 Pandemic with a Global Riposte.Infectious disorders drug targets · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Over the past 2 years, the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) caused the coronavirus disease 2019 (COVID-19) and rapidly spread worldwide. In the process of evolution, new mutations of SARS-CoV-2 began to appear to be more adaptable to the diverse changes of various cellular environments and hosts. Generally, the emerging SARS-CoV-2 variants are characterized by high infectivity, augmented virulence, and fast transmissibility, posing a serious threat to the prevention and control of the global epidemic. At present, there is a paucity of effective measurements to cure COVID-19. It is extremely crucial to develop vaccines against SARS-CoV-2 and emerging variants to enhance individual immunity, but it is not yet known whether they are approved by the authority. Therefore, we systematically reviewed the main characteristics of the emerging various variants of SARS-CoV-2, including their distribution, mutations, transmissibility, severity, and susceptibility to immune responses, especially the Delta variant and the new emerging Omicron variant. Furthermore, we overviewed the suitable crowd, the efficacy, and adverse events (AEs) of current vaccines.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.